The FDA has denied ITM Isotopes Techn | The FDA has denied ITM Isotopes Technologies’ lead pipeline candidate for a rare group of tumors due to qualms over the drug’s manufacturing.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
The FDA rejected ITM's radiopharmaceutical for neuroendocrine tumors because of manufacturing issues, delaying a potential…
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…
The FDA has rejected a radiopharmaceutical therapy due to manufacturing issues, halting what would have been a competitor for…
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio…
